Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liangbin Zhou has a total of 224 co-authors. Here are the top co-authors by number of shared publications:

  • Zhong Alan Li

    Department of Biomedical Engineering, Faculty of Engineering, The Chinese University of Hong Kong, Hong Kong SAR, China

    14 shared publications
  • Yiting Lei

    Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    9 shared publications
  • Jiankun Xu

    Department of Orthopedics&Traumatology, Disruptive Innovation Centre for Spatiotemporal Imaging in Li Ka Shing Health and Science Institute, and Joint Laboratory for Biomaterials SIAT-HKU- CUHK, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China

    8 shared publications
  • Ling Qin

    Centre for Translational Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

    8 shared publications
  • Rocky S. Tuan

    School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

    8 shared publications
  • Rocky S. Tuan

    Department of Biomedical Engineering Faculty of Engineering The Chinese University of Hong Kong Hong Kong SAR China

    5 shared publications

Latest Publications

  • Open Access

    Smart Bioinks for 4D Bioprinting: Requirements, Design, and Applications

    by Shangsi Chen, Jiahui Lai, Qiongjiao Zeng, Liangbin Zhou, Boguang Yang, Bin Zhang, Min Wang, Jiajing Zhou, Kieran Lau, Khoon S. Lim, et al.

    3D bioprinting is known for its high precision and reproducibility in fabricating complex and customized biomedical constructs. However, its applications are limited by their static nature; i.e., unlike native tissues, they cannot change shape or functionality over time. To overcome this, 4D bioprinting has emerged as a groundbreaking strategy by incorporating time as the fourth dimension, enabling dynamic structures that adapt in response to stimuli, thereby more accurately replicating living tissues. The success of 4D bioprinting hinges on the development of advanced smart bioinks, as their physicochemical properties uniquely dictate the shape‐morphing behavior, functionality, and performance of bioprinted constructs. These bioinks must be precisely engineered to respond to specific stimuli. This review first introduces 4D bioprinting technologies for tissue engineering scaffolds. We then outline essential requirements for smart bioinks and highlight how AI, particularly machine learning, is revolutionizing their design. Additionally, we examine widely used biomaterials for 4D bioprinting and discuss promising candidates for 4D printing. We also present cutting‐edge bioink applications in tissue engineering, drug screening, and disease modeling, showcasing their potential in regenerative medicine and personalized therapeutics. Finally, we discuss current challenges and future perspectives, underscoring the transformative impact of smart bioinks and 4D bioprinting on biomedical innovation.


  • Muscle Organoids and Organs-on-Chips: A 15-Year Global Bibliometric Perspective

    by Zhongxu Lv, Yuhao Yang, Ziqi Zhou, Zhuojian Cai, Liangbin Zhou, Li Jiang, Yiting Lei, Zhong Alan Li, Jia Li, Xiaoshuai Wang

    Muscle organoids and Organs-on-Chips (OoCs) have emerged as advanced strategies in regenerative medicine and preclinical investigation for muscular diseases. Here, we aim to conduct a comprehensive bibliometric analysis to reveal the global research trends and their evolution in these fields. We retrieved studies on muscle organoids and OoCs published between 2010 and 2025 were retrieved from the Web of Science Core Collection (WoSCC), Scopus, and PubMed databases. Quantitative mapping of publication trends, academic impact, and research hotspots was conducted using R-bibliometrix, VOSviewer, and CiteSpace. A total of 2,083 articles (cardiac, n = 990; smooth, n = 921; and skeletal, n = 261, subgroups are nonexclusive categories) were included. Global publications have expanded rapidly since 2016, achieving an average annual growth rate of 26.0% and peaking in 2025. The United States and China emerged as leading countries in both publication and citation numbers, and Harvard University took the lead among different institutions. Thematic analysis revealed a developmental trajectory evolving from fundamental material engineering (e.g., biosensors) toward functional validation (e.g., drug screening) and sophisticated microenvironment reconstruction (e.g., vascularization and barrier functions). Furthermore, multidimensional metrics suggested a synchronized pattern of academic impact and developmental focus across all three muscle types. This bibliometric analysis reveals a thematic evolution in research priorities, moving beyond generic microfluidic design to addressing systemic tissue engineering bottlenecks, specifically perfusable vascularization, neuromuscular innervation, and multilineage maturation. These findings offer a bibliometric overview that can inform future efforts toward platform standardization, high-throughput screening, and clinical translation for muscular diseases.

  • Open Access

    3D printing of cell‐free implants: A promising avenue for cartilage regeneration and joint preservation

    by Liangbin Zhou, Shangsi Chen, Boguang Yang, Yiting Lei, Hegeng Li, Haoyue Luo, Xiaoshuai Wang, Qiongjiao Zeng, Jiahui Lai, Fei Jin, et al.

    Cartilage regeneration and joint preservation are confronted with tremendous challenges. Traditional cell‐based treatments, while effective in some cases, still encounter many limitations, including immunogenicity, high costs, and logistical problems concerning cell sourcing, in vitro expansion, and storage. Recent progress in 3D printing technologies offers a promising alternative: 3D‐printed cell‐free implants. By exploiting biomaterial‐driven activation and augmentation of the pro‐regenerative roles of endogenous stem/progenitor cells (ESPCs), via spatiotemporally controlled biophysical and biochemical cues, these medical devices can offer a scalable patient‐specific solution for cartilage or osteochondral regeneration. This perspective article argues that their success hinges on optimizing intricate scaffold design and fabrication to mimic native tissue hierarchy, elucidating ESPC recruitment and repair mechanisms, and addressing regulatory barriers to clinical translation. Fulfilling these criteria could democratize access to regenerative care while circumventing the ethical and practical pitfalls of exogenous cell‐ and in vitro‐expanded autologous cell‐based interventions.

  • Open Access

    In vitro models of blood-spinal cord barrier in spinal cord injury: A meta-analysis of model design, performance, and physiological relevance

    by Yuwei Zhang, Songlin He, Yiting Lei, Peixi Wang, Liangbin Zhou, Hengxing Zhou, Gang Lu, Sheung-Wai Law, Patrick Shu-Hang Yung, Shiqing Feng, et al.

    Background: In vitro models of the blood-spinal cord barrier (BSCB) are widely utilized for developing therapeutics against neurological diseases such as spinal cord injury (SCI). However, high variability among existing in vitro BSCB models severely limits their predictive power for preclinical research, highlighting the need for a comprehensive synthesis of current model characteristics and performance. Methods: We first reviewed in vitro BSCB models under SCI conditions and conducted a comprehensive meta-analysis of mainstream Transwell-based models. The synthesis systematically analyzed critical factors influencing model performance, including cell types, disease modeling strategies ( e.g., hypoxic culture, inflammatory stimuli, oxidative stress), and the inclusion of biomaterial matrices. The meta-analysis quantified differences in key BSCB properties, including permeability, transendothelial electrical resistance (TEER), and junctional/inflammatory protein expression, across healthy, diseased, and treatment contexts. Results: The synthesis identified cell composition, disease induction methods, and biomaterial matrix inclusion as core factors determining the ability of in vitro BSCB models to replicate physiological and pathological characteristics. Meta-analysis results revealed significant quantitative differences among three types of BSCB models. Specifically, disease models exhibited consistently higher permeability (measured via FITC-dextran) and lower mean TEER values (97.94 Ω·cm 2 ) compared to healthy models (183.73 Ω·cm 2 ) and treatment groups (146.28 Ω·cm 2 ). Additionally, co-culturing BSCB endothelial cells with glial cells or pericytes was demonstrated to significantly enhance the physiological relevance of the models. Conclusions: This review consolidates critical insights into in vitro BSCB model design and performance, providing a clear framework for developing more accurate and reliable models. These findings will facilitate the development of effective therapeutic interventions capable of crossing the BSCB, addressing a key bottleneck in mechanistic research and therapeutic development for treating SCI and other neurological diseases.

  • Open Access

    The organ-on-a-chip–AI virtual cell loop: a path toward next‑generation biomedicine

    by Danli Cui, Liangbin Zhou, Charlotte A.E. Hauser, Zhong Alan Li, Yiting Lei


  • Open Access

    Microelectrodes enable dynamic biointerfaces for closed-loop organs-on-chips

    by Haoyue Luo, Liangbin Zhou, Fei Jin, Sumin Bian, Cheng Jiang, Yong Chen, Chenzhong Li, Rocky S. Tuan, Zhong Alan Li


  • Open Access

    Model-as-evidence framework established using AI-integrated organoids and organs-on-chips systems

    by Peixi Wang, Berenica Santoso, Songlin He, Liangbin Zhou, Yuwei Zhang, Yichi Zhang, Shing Yui Ho, Rocky S. Tuan, Zhong Alan Li

    The predictive capability crisis in drug discovery and development remains a significant factor hindering medical progress. Among emerging solutions, organoids offer the ability to reflect the biological fidelity of tissues, whereas organs-on-chips (OoCs) demonstrate strengths in simulating dynamic tissue microenvironments and enabling multi‑organ interactions. Herein, we present a unifying artificial intelligence (AI)-orchestrated framework that incorporates both platforms into verifiable and regulatable “model-as-evidence” (MAE) pathways capable of self-optimization with researcher oversight. AI is employed as an indispensable computational integration layer addressing three bottlenecks that render conventional approaches infeasible: (i) combinatorial explosion in high-dimensional parameter spaces, (ii) multi-scale coupling between molecular interactions and tissue-scale level morphogenesis, and (iii) requirement for real-time adaptive control of dynamic microenvironments exceeding human cognitive bandwidth. At the organoid level, this integration enables multi‑objective optimization to improve reproducibility, reduce resource use, and achieve predictive modeling to capture extracellular matrix–cells interactions. For OoCs, active learning algorithms condense protracted design cycles into efficient, goal-directed experimentation, and deep reinforcement learning sustains physiological steady states through adaptive, real-time control. The convergence of these systems within an integrated platform enables standardized, cross-comparable phenotyping pipelines that transform heterogeneous experimental data into a universal quantitative language, and harmonized evaluation benchmarks align experimental outputs across laboratories. Together, this framework generates curated evidence packages that directly address regulatory concerns related to efficacy and safety. By systematizing experimental design, parameter control, and interpretive analytics, this AI-orchestrated approach elevates organoid and OoC technologies from specialized crafts to a robust engineering discipline. It establishes a virtuous cycle wherein AI accelerates iterative validation and optimization, freeing researchers to focus on higher-order hypothesis generation and translational strategy. Thus, through AI-orchestrated quantification of biological fidelity and engineering rigor, these platforms may mature into credible, scalable, and transformative toolboxes for next-generation biomedical translation.


  • Open Access

    Reframing Preclinical Evaluation: Decoding FDA's 2026 Guidance on New Approach Methodologies

    by Zhongjun Wan, Xisheng Li, Hongdou Li, Liangbin Zhou


  • Open Access

    Refining Osteoarthritis Risk Prediction: Average Sagittal Abdominal Diameter Complements and Enhances Body Mass Index With Sex‐Specific Insights From National Health and Nutrition Examination Survey

    by Yuwei Zhang, Xiaoshuai Wang, Hu Zhu, Haowei Chen, Zhaohua Zhu, Liangbin Zhou, Michael Tim Yun Ong, Dongquan Shi, Xin Zhang, David J. Hunter, et al.

    Background: Osteoarthritis (OA), the most prevalent joint disease and a leading cause of disability globally, has its disease burden inadequately captured by body mass index (BMI). As the sole quantified risk factor in current Global Burden of Disease estimates, BMI accounted for only 20% of OA burden. A critical limitation of BMI is its inability to distinguish fat distribution patterns, particularly abdominal adiposity, which is increasingly recognized as a key driver of metabolic and musculoskeletal pathologies. Herein, we hypothesize that anthropometric indicators reflecting central adiposity, such as average sagittal abdominal diameter (ASAD), may outperform BMI in predicting OA risk, especially when considering sex and age differences. Methods: This cross‐sectional study analyzed 27,791 National Health and Nutrition Examination Survey participants (1999–2023) with complete OA diagnosis, anthropometric, and metabolic data. Participants were stratified by sex and age (40‐year cutoff). Multivariable logistic regression, adjusted for confounders, estimated predictor‐OA associations via standardized odds ratios (sORs), and these associations were evaluated by the area under the receiver operating characteristic curve (AUROC). Data were split into training (70%) and validation (30%) sets, with DeLong's test comparing different predictors against BMI. Results: In the overall population, ASAD showed a stronger association with OA (sOR = 1.483) than BMI (sOR = 1.436), with comparable validation AUROC (ASAD: 0.857; BMI: 0.854). Sex‐stratified analysis revealed that BMI was the optimal predictor for males (sOR = 1.466; validation AUROC = 0.844), while ASAD outperformed BMI in females (sOR = 1.486 vs. 1.450; validation AUROC = 0.865 vs. 0.863). Further age stratification revealed that in males under 40, both BMI (sOR = 1.261; validation AUROC = 0.750) and ASAD (sOR = 1.194; validation AUROC = 0.889) were the strongest predictors, and that ASAD (sOR = 1.490; validation AUROC = 0.769) and BMI (sOR = 1.482; validation AUROC = 0.736) remained strong for males aged 40 and above. In age‐stratified analyses of females, ASAD showed the strongest consistent association with OA risk, both in participants under 40 (sOR = 1.472; validation AUROC = 0.801) and those aged 40 and above (sOR = 1.421; validation AUROC = 0.764). Conclusions: ASAD emerges as a superior predictor for females and a competitive population‐level complement to BMI. BMI remains an optimal OA predictor for males. Within the National Health and Nutrition Examination Survey framework, these findings underscore the necessity of integrating abdominal adiposity metrics, particularly ASAD, into OA risk assessment to improve sex‐specific prevention strategies.